NASDAQ · ERAS
Erasca, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ERAS: Nov 11, 2026
Erasca, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.14. The reported EPS for the same quarter last year was $-0.11.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.14 | $-0.13 | $-0.14 | 6 |
| Dec 2026 | $-0.13 | $-0.12 | $-0.15 | 5 |
| Mar 2027 | $-0.14 | $-0.14 | $-0.14 | 4 |
| Jun 2027 | $-0.16 | $-0.15 | $-0.16 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · RTTNews · Zacks · The Motley Fool- BNK Invest · Sep 25, 3:20 PM EDTNotable Friday Option Activity: APP, ERAS, CRDOLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Applovin Corp (Symbol: APP), where a total volume of 44,303 contracts has been traded thus far today, a contract volume which is representative of approximately
- RTTNews · Aug 24, 9:00 AM EDTErasca's Pancreatic Cancer Drug Gains FDA Fast Track Designation(RTTNews) – Monday, Erasca, Inc. (ERAS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma.
- BNK Invest · Jul 31, 10:48 AM EDTXBI, APGE, ORKA, ERAS: ETF Outflow AlertLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $382.4 million dollar outflow — that's a 3.7% decrease week over week
- BNK Invest · Jul 16, 9:00 AM EDTErasca Reaches Analyst Target PriceIn recent trading, shares of Erasca Inc (Symbol: ERAS) have crossed above the average analyst 12-month target price of $20.80, changing hands for $21.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation
- RTTNews · Jul 14, 5:12 AM EDTErasca Updates Phase 1 Data, Outlines Development Plans For ERAS-0015; Prices $550 Mln Offering(RTTNews) – Erasca, Inc. (ERAS), a clinical-stage precision oncology company, updated preliminary Phase 1 data for its investigational candidate, ERAS-0015, in patients with RAS-mutant solid tumours and provided development plans. In addition, Erasca priced an upsized public offe
- Zacks · Jul 2, 10:50 AM EDTTango Therapeutics Rides a New Precision Oncology Trend in 2026TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
- Zacks · Jul 2, 10:46 AM EDTIs TNGX Stock Still Worth Buying After Its Huge Rally in 2026?Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
- Zacks · Jul 2, 10:43 AM EDTTNGX Stock Outlook Hinges on Vopimetostat and Key 2026 CatalystsTango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.
- BNK Invest · Jun 29, 3:42 PM EDTNoteworthy Monday Option Activity: VZ, ERAS, OUSTAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Verizon Communications Inc (Symbol: VZ), where a total of 169,969 contracts have traded so far, representing approximately 17.0 million underlying shares. That amounts t
- Zacks · Jun 9, 12:44 PM EDTTNGX Stock Jumps 53% on Early Pancreatic Cancer Study ResultsTango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
- The Motley Fool · May 29, 8:47 PM EDTWhy This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%RTW Investments bought 16,010,524 shares of Erasca last quarter; the estimated transaction value was $189.23 million based on the quarter's average share price.
- The Motley Fool · May 18, 4:00 PM EDTBiotech Fund Sells $44.5 Million Erasca Stake After Massive 700% RallySold 3,766,393 shares of Erasca; estimated trade value $44.52 million (based on average close in Q1 2026).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Erasca, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.